Tysabri Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

G öttingen pigs as a potential model for natalizumab pharmacokinetics, pharmacodynamics, and immunogenicity evaluation
Biomed Pharmacother. 2022 Oct 26;156:113926. doi: 10.1016/j.biopha.2022.113926. Online ahead of print.ABSTRACTNatalizumab is a recombinant, humanized form of a monoclonal antibody that binds to CD49d. The presented study was conducted to explore the suitability of Göttingen pigs as a pharmacokinetic/pharmacodynamic model in the preclinical phase of biosimilar natalizumab development. The minipigs were treated with 1.286 or 3.0 mg of natalizumab (Tysabri®) per kg of body weight by a single 1-hour intravenous infusion. Six days before (baseline) and 30 days after administration of the single dose of natalizumab, blood samp...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - October 29, 2022 Category: Drugs & Pharmacology Authors: Tomasz Grabowski Rafa ł Derlacz Artur Burma ńczuk Source Type: research

A case of natalizumab ‐associated progressive multifocal leukoencephalopathy followed by immune reconstitution inflammatory syndrome with difficulty in the timing of immunotherapy
ConclusionsTreatment sequencing should be executed before the onset of NAT-PML. Changes in CSF cell count and IgG index may be useful for treatment decision; further research is needed. (Source: Clinical and Experimental Neuroimmunology)
Source: Clinical and Experimental Neuroimmunology - October 19, 2022 Category: Neurology Authors: Takamichi Sugimoto, Shuichiro Neshige, Shiro Aoki, Kazuhide Ochi, Ruoyi Ishikawa, Megumi Nonaka, Masahiro Nakamori, Tomohisa Nezu, Kazuo Nakamichi, Yu Yamazaki, Hirofumi Maruyama Tags: CASE REPORT Source Type: research

Soluble Vascular Cell Adhesion Molecule-1 (sVCAM-1) and Natalizumab Serum Concentration as Potential Biomarkers for Pharmacodynamics and Treatment Response of Patients with Multiple Sclerosis Receiving Natalizumab
ConclusionsSoluble vascular cell adhesion molecule 1 is a suitable pharmacodynamic marker during treatment with NTZ, which is significantly reduced already after the first dose, remains stable in individual patients even on extended interval dosing, and strongly correlates with NTZ SC. Because of the high inter-individual range, absolute levels of sVCAM-1 and NTZ SC are difficult to introduce as treatment monitoring biomarkers in order to predict disease activity in single patients. (Source: CNS Drugs)
Source: CNS Drugs - September 29, 2022 Category: Neurology Source Type: research

Persistence, Adherence, and Switching to Higher-Cost Therapy in Patients with Multiple Sclerosis Initiating Oral Disease-Modifying Therapies: A Retrospective Real-World Study
ConclusionPatients newly initiated on teriflunomide and fingolimod had better real-world persistence and adherence at 6 and 12 months, and longer time to switch to higher-cost therapies, than patients on dimethyl fumarate or diroximel fumarate. (Source: Neurology and Therapy)
Source: Neurology and Therapy - September 24, 2022 Category: Neurology Source Type: research

Superior effects of natalizumab versus other DMTs on patient-reported outcomes in people with multiple sclerosis
Conclusions Natalizumab was associated with superior outcomes over time for many patient-reported health and employment outcomes when compared with other DMTs in this large prospective cohort study. These findings may influence treatment selection in clinical practice and future treatment cost-effectiveness analyses. (Source: Journal of Neurology, Neurosurgery and Psychiatry)
Source: Journal of Neurology, Neurosurgery and Psychiatry - September 14, 2022 Category: Neurosurgery Authors: Chen, J., Diouf, I., Taylor, B. V., Kalincik, T., van der Mei, I. Tags: Multiple sclerosis Source Type: research

Improvements in Cognitive Processing Speed, Disability, and Patient-Reported Outcomes in Patients with Early Relapsing-Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4-year, Real-World, Open-Label Study
ConclusionThese results further extend our knowledge of the effectiveness, specifically regarding improvements in cognitive processing speed, disability and PROs, of long-term natalizumab treatment in early RRMS patients.Clinicaltrials.govNCT01485003 (5 December 2011) (Source: CNS Drugs)
Source: CNS Drugs - September 5, 2022 Category: Neurology Source Type: research

Pharmacological Management of Inflammatory Bowel Disease: a Century of Expert Opinions in Cecil Textbook of Medicine
Conclusions: The pharmacological management of IBD has been the focus of intense research and development in the past 60 years. The pillars of drug treatment have been 5-aminosalicylates and corticosteroids. Recent pharmacological innovations (immunomodulators and biologicals) constitute an encouraging paradigm shift in the treatment of UC and Crohn disease. (Source: American Journal of Therapeutics)
Source: American Journal of Therapeutics - September 1, 2022 Category: Drugs & Pharmacology Tags: Original Investigation Source Type: research